In an older adult diagnosed with an abdominal aortic aneurysm and no other atherosclerotic disease, should low‑dose aspirin be started?

Aspirin for Abdominal Aortic Aneurysm Without Other Atherosclerotic Disease

In an older adult diagnosed with an isolated abdominal aortic aneurysm (AAA) without concomitant atherosclerotic disease, low-dose aspirin should NOT be routinely started. 1

Guideline-Based Recommendation

The most recent and authoritative guidance comes from the 2024 ESC Guidelines, which explicitly state that anticoagulation or dual antiplatelet therapy should not be used routinely in patients with aortic aneurysms, as these agents provide no benefit and significantly increase bleeding risk. 2 The 2022 ACC/AHA Guidelines provide a Class IIb (Level C-LD) recommendation—meaning aspirin may be considered in AAA patients, but only when there is concomitant atheroma and/or penetrating atherosclerotic ulcer (PAU). 1

Key Distinction: Isolated AAA vs. AAA with Atherosclerotic Disease

• If the AAA is isolated (no atheroma, no PAU, no coronary artery disease): Aspirin is not indicated. 1, 2

• If the patient has severe/complex aortic atheroma (≥4 mm thickness, mobile or ulcerated components) or documented coronary artery disease: Single antiplatelet therapy (SAPT) with low-dose aspirin 75–100 mg daily should be considered for cardiovascular risk reduction. 1, 3

Evidence Base and Rationale

Why Aspirin Is Not Routinely Recommended

The role of antithrombotic therapy in aortic aneurysms remains uncertain, with conflicting observational data regarding aneurysm growth rates. 1 While low-dose aspirin is not associated with higher AAA rupture risk, it could worsen prognosis if rupture occurs. 1

The Danish National Registry study (4,010 patients) demonstrated that preadmission aspirin use was associated with:

• No reduction in rupture risk (adjusted OR 0.97; 95% CI 0.86–1.08) 4
• Increased 30-day case fatality after rupture (66% in aspirin users vs. 57% in non-users; adjusted mortality rate ratio 1.16; 95% CI 1.06–1.27) 5, 4

This nearly 20% excess mortality after rupture in aspirin users is a critical safety concern. 5

Limited Evidence for Benefit

One small cohort study suggested aspirin may slow AAA growth in medium-sized aneurysms (40–49 mm), with expansion rates of 2.92 mm/year in aspirin users vs. 5.18 mm/year in non-users. 6 However, this finding:

• Was not replicated in larger population-based studies 7
• Applies only to a narrow size range (40–49 mm), not to smaller aneurysms (<40 mm) 6
• Cannot exclude residual confounding 6

When to Consider Aspirin in AAA Patients

Aspirin should be considered only when the patient has:

1. Concomitant coronary artery disease: SAPT is recommended for secondary prevention of myocardial infarction and stroke. 1

2. Severe/complex aortic atheroma: Defined as atheroma ≥4 mm thickness or presence of mobile/ulcerated components. 3 In this setting, atherosclerotic AAA is considered a coronary artery disease equivalent with >20% risk of major cardiovascular events within 10 years. 1, 3

3. Polyvascular disease: If the patient is symptomatic in at least one vascular territory and has no high bleeding risk, combination therapy with rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily should be considered. 2

Contraindications and Bleeding Risk Assessment

Do not initiate aspirin if any of the following are present:

• Active gastrointestinal bleeding 3
• History of peptic ulcer disease or previous GI hemorrhage 1
• Known aspirin allergy or hypersensitivity 3
• Thrombocytopenia or coagulopathy 1
• Concurrent use of anticoagulants (unless specifically indicated for atrial fibrillation) 1
• Age >70 years (higher bleeding risk) 1
• Chronic kidney disease 1

Optimal Medical Management for Isolated AAA

Instead of aspirin, focus on the following evidence-based interventions:

1. Cardiovascular Risk Factor Management

• Smoking cessation is mandatory—the single most important modifiable risk factor for AAA development, growth, and rupture. 1, 3
• Blood pressure control to <130/80 mm Hg to reduce rupture risk. 1
• Statin therapy with target LDL-C <1.4 mmol/L (<55 mg/dL) to reduce major adverse cardiovascular events. 2, 3

2. Surveillance Imaging

• Every 6 months for AAA 50–55 mm in men or 45–50 mm in women 1
• Annually for AAA 40–49 mm in men or 40–44 mm in women 1
• Every 3 years for AAA 30–39 mm 1
• Every 4 years for aortic diameter 25–29 mm with life expectancy >2 years 1

3. Avoid Fluoroquinolones

Fluoroquinolones should be avoided unless there is a compelling clinical indication with no reasonable alternative, as they increase the risk of aortic complications. 1, 2, 3

Clinical Pitfalls to Avoid

• Do not assume all AAA patients need aspirin: The diagnosis of AAA alone is not an indication for antiplatelet therapy. 1, 2

• Do not overlook bleeding risk: In older adults with AAA, the harm from aspirin-related bleeding (especially if rupture occurs) may outweigh any cardiovascular benefit. 5, 4

• Do not withhold aspirin if there is established coronary artery disease: In this scenario, aspirin is indicated for secondary prevention, not for the AAA itself. 1

• Do not use dual antiplatelet therapy or anticoagulation routinely: These agents provide no benefit in isolated AAA and significantly increase bleeding risk. 2